Navigation Links
Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
Date:2/1/2010

RICHMOND, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 9:00 am ET on Monday, February 8, 2010 at the 12th Annual BIO CEO & Investor Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
http://www.sangamo.com

'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
2. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
3. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
4. Sangamo Announces Pricing of Public Offering of Common Stock
5. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
6. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
7. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
8. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
9. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
11. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Only nine percent of ... over profits, while only 16 percent believe health insurance ... today. Meanwhile, 36 percent of U.S. adults believe health ... over profits, compared to hospitals (23%). "We ... said Wendy Salomon , vice president of reputation ...
(Date:1/17/2017)... ... January 17, 2017 , ... One Million Solutions in ... $3 million in investment towards 15+ TEC Validation Projects™. As a pre-competitive consortium, ... applicability in drug safety assessment, for the industry as a whole. , Through ...
(Date:1/17/2017)... , Jan. 17, 2017  On January 10 ... 35th Annual J.P. Morgan Healthcare Conference in ... D. Kittle, Jr. , spoke to pharmaceutical leaders and ... by ProclaRx to break down and destroy biofilms.  ... bacteria and prevent antibiotics and the body,s immune system ...
(Date:1/16/2017)...  Eurofins Genomics today announced the expansion of its ... receive their primers in a shorter turnaround time, without ... with other providers. Express oligos are available for anyone ... no additional fee. Researchers use the oligos ... sequencing, genotyping, site-directed mutagenesis, and cloning. Often, they are ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):